BBDO
BANK BRADESCO
$2.91
-3.64%
$31.9B
No data for this timeframe.
Vol
Market Cap$31.9B
Cap SizeLarge Cap
Inst. Holders3 funds
Inst. Value$457.8K
Inst. Activity1 buys / 0 sells
SEC Reports7
Recent Activity
May 29, 2026
SEC
Bradesco filed its 2025 Reference Form (annual report) on Form 6-K, reporting net income of R$23.673 billion, ROAE of 13
6-K — Impact 3/10
May 13, 2026
SEC
Banco Bradesco filed a routine Form 6-K disclosing insider shareholding positions and transactions for April 2026. The f
6-K — Impact 2/10
May 7, 2026
SEC
Bradesco reported strong 1Q26 results with recurring net income up 16.1% YoY to R$6.8 billion and total revenue increasi
6-K — Impact 7/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
11,710 shares ($33.6K)
Inst.
MORGAN STANLEY — ADD
111,002 shares ($325.2K)
Analyst Ratings
5Strong Buy
8Buy
5Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2016 | Barclays | DOWNGRADE | Overweight → Equal-Weight |
Latest Reports
NEUTRAL
6-K
3/10
Bradesco filed its 2025 Reference Form (annual report) on Form 6-K, reporting net income of R$23.673 billion, ROAE of 13
May 29, 2026
NEUTRAL
6-K
2/10
Banco Bradesco filed a routine Form 6-K disclosing insider shareholding positions and transactions for April 2026. The f
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $335.6K | ADD |
| FMR LLC | $88.6K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $33.6K | NEW |
3 institutional holders with $457.8K total value (159,504 shares) as of 2025-Q4. Top holders: MORGAN, FMR, RENAISSANCE. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 116,918 | $335.6K | 73.3% | ADD +26.5% |
| 2 | FMR LLC | 30,876 | $88.6K | 19.4% | ADD +50.4% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 11,710 | $33.6K | 7.3% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 11,710 | — | $33.6K | 2025-Q4 |
| MORGAN STANLEY | ADD | 87,721 | 111,002 | +26.5% | $325.2K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 184,615 | 87,721 | -52.5% | $239.5K | 2025-Q2 |
| UBS Group AG | TRIM | 2,962 | 1,250 | -57.8% | $3.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 17,059 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | NEW | — | 44,251 | — | $92.0K | 2025-Q1 |
| FMR LLC | ADD | 21,612 | 32,502 | +50.4% | $67.6K | 2025-Q1 |
| UBS Group AG | DOUBLED | 221 | 2,962 | +1240.3% | $6.2K | 2025-Q1 |
| MORGAN STANLEY | ADD | 109,841 | 179,827 | +63.7% | $321.9K | 2024-Q4 |
| CITADEL ADVISORS LLC | EXIT | 20,919 | 0 | -100.0% | $0.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.4/10.
NEUTRAL
6-K
3/10
Bradesco filed its 2025 Reference Form (annual report) on Form 6-K, reporting net income of R$23.673
May 29, 2026
NEUTRAL
6-K
2/10
Banco Bradesco filed a routine Form 6-K disclosing insider shareholding positions and transactions f
May 13, 2026
BULLISH
6-K
7/10
Bradesco reported strong 1Q26 results with recurring net income up 16.1% YoY to R$6.8 billion and to
May 7, 2026
BEARISH
6-K
6/10
Bradesco's Q1 2026 net income fell 7.8% YoY to R$5.23B from R$5.68B, with net interest income declin
May 7, 2026
BULLISH
6-K
7/10
Banco Bradesco reported strong 1Q26 results with recurring net income of R$6.8 billion, up 16.1% y/y
May 7, 2026
NEUTRAL
6-K
2/10
Banco Bradesco filed a 6-K report, which is a routine disclosure required of foreign private issuers
Apr 10, 2026
NEUTRAL
6-K
4/10
Banco Bradesco filed a 6-K disclosing shareholder voting results for a partial spin-off of Bradseg P
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Apr 2016): 72% buy across 18 analysts — 5 strong buy, 8 buy, 5 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $37.5B | 10.2% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $38.2B | 9.2% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $150.2B | 9.4% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $161.4B | 7.4% | — |
1 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2016 | Barclays | DOWNGRADE | Overweight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 8 | 5 | 0 | 0 | 72% | |
| May 1, 2026 | 5 | 8 | 5 | 0 | 0 | 72% | |
| Apr 1, 2026 | 5 | 8 | 5 | 0 | 0 | 72% | |
| Mar 1, 2026 | 5 | 8 | 5 | 0 | 0 | 72% | |
| Feb 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% | |
| Jan 1, 2026 | 5 | 8 | 6 | 0 | 0 | 68% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.